“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in EUR
Last close As at 01/06/2023
EUR8.61
▲ −0.08 (−0.92%)
Market capitalisation
EUR195m
Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. The development process combines the expertise of a wide range of technical and medical experts.
Healthcare
Healthcare
Healthcare
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (2.4) | (21.8) | (17.4) |
| Relative | (7.4) | (25.3) | (27.4) |
| 52 week high/low | €14.8/€8.0 |
Edison Investment Research is terminating coverage on Carmat (ALCAR). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
| Y/E Dec | Revenue (€m) | EBITDA (€m) | PBT (€m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2020A | 0.0 | N/A | (38.7) | (285.32) | N/A | N/A |
| 2021A | 2.2 | N/A | (61.9) | (402.00) | N/A | N/A |
| 2022E | N/A | N/A | N/A | N/A | N/A | N/A |
| 2023E | N/A | N/A | N/A | N/A | N/A | N/A |
Managing Director - Head of Content, Healthcare
Get access to the very latest content matched to your personal investment style.
